Joint Formulary & PAD

Erdosteine - Reduction of sputum viscosity

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Tablets
Associated Icons :
Guidelines BNF SPC
NFD1
Un
Restrictions / Comments :
Important
Not licensed for this indication - refer to guidelines for alternatives

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Erdosteine
Indication :
Reduction of sputum viscosity
Group Name :
Keywords :
mucolytics, excessive mucous production
Brand Names Include :
Erdotin
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
0

Other Indications

Below are listed other indications that Erdosteine is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Reduction of sputum viscosity.

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.